CoChat

Pediatrics Efficacy and Safety of Naltrexone Use in Pediatric Patients with Autistic Disorder

Eichaar, Gladys M, Maisch, Nicole M, Augusto, Laura M Gianni, Wehring, Heidi J · 2006 · Annals of Pharmacotherapy
Cited by 73

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Objective: To review the efficacy and safety of naltrexone in pediatric patients with autistic disorder (AD). Data Sources: Using the terms pediatric, child, naltrexone, autism, and autistic disorder, a literature search was performed using MEDLINE (1966–May 18, 2006) and the International Pharmaceutical Abstracts (1971–May 18, 2006) database. The references of these articles were scanned for additional relevant literature. Study Selection and Data Extraction: All articles describing or evaluating the efficacy and/or safety of naltrexone in pediatric patients with AD were included in this review. Three case reports, 8 case series, and 14 clinical studies were identified as pertinent. Data Synthesis: Naltrexone has been used most commonly at doses ranging from 0.5 to 2 mg/kg/day and found to be predominantly effective in decreasing self-injurious behavior. Naltrexone may also attenuate hyperactivity, agitation, irritability, temper tantrums, social withdrawal, and stereotyped behaviors. Patients may also exhibit improved attention and eye contact. Transient sedation was the most commonly reported adverse event. Small sample size, short duration, and inconsistent evaluative methods characterize the available research. Conclusions: A child affected by AD may benefit from a trial of naltrexone therapy, particularly if the child exhibits self-injurious behavior and other attempted therapies have failed. Serious adverse effects have not been reported in short-term studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1345/aph.1g499

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 30

  1. First MB, ed. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
  2. 10.1097/00004703-199510000-00002 · DOI
  3. 10.1542/peds.108.5.1155 · DOI · Paper page
  4. 10.1542/peds.2004-1958 · DOI · Paper page
  5. 10.1177/088307380401900301.155 · DOI · Paper page
  6. McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003;64(suppl 4): 16–25.
  7. 10.1016/0166-2236(79)90071-7 · DOI · Paper page
  8. 10.1002/ana.410220419 · DOI · Paper page
  9. 10.1016/S0140-6736(88)91525-5 · DOI
  10. Campbell M, Adams P, Small AM, Tesch LM, Cunen EL. Naltrexone in infantile autism. Psychopharmacol Bull 1988;24:135–9.
  11. 10.1159/000480957 · DOI
  12. Barrett RP, Feinstein C, Hole WT. Effects of naloxone and naltrexone on self-injury: a double-blind, placebo-controlled analysis. Am J Ment Retard 1989;93:644–51.
  13. 10.1007/BF02284716 · DOI
  14. 10.1007/BF02284764 · DOI
  15. Lensing P, Klingler D, Lampi C., Naltrexone open trial with a 5-year-old-boy. A social rebound reaction. Acta Paedopsychiatr 1992; 55:169–73.
  16. Akkok F. The effects of naltrexone in autistic children: report of two cases. Turk J Pediatr 1995;37:19–23.
  17. 10.1023/A:1005674016014 · DOI · Paper page
  18. Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Chorocco MC. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol Bull 1990;26:130–5.
  19. Ernst M, Devi L, Silva RR, . Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacol Bull 1993;29:221–7.
  20. Gonzalez NM, Campbell M, Small AM, . Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychopharmacol Bull 1994;30:203–8.
  21. 10.1016/0165-1781(95)02749-M · DOI
  22. 10.1097/00004583-199502000-00018 · DOI
  23. 10.1016/0006-3223(95)00297-9 · DOI
  24. Scifo R, Cioni M, Nicolosi A., Opioid-immune interactions in autism: behavioural and immunological assessment during a doubleblind treatment with naltrexone. Ann Ist Super Sanita 1996;32:351–9.
  25. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997;36:1570–8.
  26. 10.1016/S0924-977X(99)00010-3 · DOI
  27. 10.1097/00004583-199905000-00021 · DOI
  28. 10.1023/A:1023000929040 · DOI
  29. 10.1097/00004583-199808000-00006 · DOI
  30. 10.1177/106002809703101102 · DOI

Cited by

See all 73

Metadata

Authors
Eichaar, G. M., Maisch, N. M., Augusto, L. M. G., & Wehring, H. J.
Venue
Annals of Pharmacotherapy
Published
2006-06
Volume
40
Issue
6
Pages
1086-1095
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2102096940
Cited by
73
References
8
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.